Physician profile
Daniel Moscow
NPI 1124067350
$2,316.66
in general payments reported to CMS, 2019-2025
28 companies · $923 in 2025
The $923 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $153 · 2021: $67.84 · 2023: $116 · 2024: $671 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,710.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $412.29 | 2019-2025 | Wegovy |
| Lilly USA, LLC | $327.18 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $262.53 | 2019-2025 | |
| Pfizer INC. | $160.24 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $141.40 | 2019-2025 | Airsupra, Breztri |
| Welch Allyn | $99.14 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $92.66 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Sanofi Pasteur INC. | $85.36 | 2019-2024 | |
| Dexcom, INC. | $74.52 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $69.72 | 2024-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $67.91 | 2024-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $58.89 | 2024-2025 | Veozah |
| Daiichi Sankyo INC. | $58.00 | 2024-2025 | Injectafer |
| Glaxosmithkline, LLC. | $53.64 | 2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Shield Therapeutics INC | $44.81 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $42.64 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $41.61 | 2025 | Rexulti |
| Amgen INC. | $36.10 | 2019 | |
| Boston Scientific Corporation | $29.76 | 2024 | Wavewriter Alpha Prime 16 |
| Actelion Pharmaceuticals US, INC. | $24.95 | 2025 | Opsumit, Uptravi |
| Axsome Therapeutics, INC. | $22.08 | 2025 | Auvelity |
| Inspire Medical Systems, INC. | $20.06 | 2025 | Inspire |
| Amarin Pharma, INC. | $18.77 | 2019 | |
| Medicomp INC | $17.50 | 2025 | Telepatch Cardiac Monitor |
| Genentech USA, INC. | $17.45 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.27 | 2025 | Zoryve |
| Hikma Pharmaceuticals USA | $12.57 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Moscow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.